Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

• Päätekijät: Hoai‐Thu Thai (Tekijä), Kimiko Koiwai (Tekijä), Yoshihisa Shitara (Tekijä), Hirotaka Kazama (Tekijä), Jean‐Baptiste Fau (Tekijä), Dorothée Semiond (Tekijä), Christine Veyrat‐Follet (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2023-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of serum M‐protein kinetics and its association with p...